Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;43(11):1914-1921.
doi: 10.1097/IAE.0000000000003870.

ASSOCIATION OF ORAL MONTELUKAST WITH REDUCED ODDS OF DEVELOPING EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Wataru Matsumiya  1   2 , Irmak Karaca  1 , Brandon Huy Pham  1 , Amir Akhavanrezayat  1 , Gunay Uludag  1 , Cigdem Yasar  1 , Hashem Ghoraba  1 , Azadeh Mobasserian  1 , Jonathan Regenold  1 , Muhammad Sohail Halim  1   3 , Yasir J Sepah  1 , Diana V Do  1 , Victor Chong  4 , Quan Dong Nguyen  1
Affiliations

ASSOCIATION OF ORAL MONTELUKAST WITH REDUCED ODDS OF DEVELOPING EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Wataru Matsumiya et al. Retina. .

Abstract

Purpose: This study was conducted to evaluate the association of oral montelukast, selective antagonism for cysteinyl leukotriene receptor 1, with reduced odds of exudative age-related macular degeneration (exAMD) development.

Methods: This case-control study was conducted using institutional cohort finder tool, and included 1913 patients with exAMD (ICD: H35.32 and 362.52) and 1913 age- and gender-matched control subjects without exAMD. Subanalysis among 1913 exAMD and 324 nonexudative AMD was also conducted.

Results: A total of 47 (2.5%) exAMD cases were identified to have a history of oral montelukast use before exAMD diagnosis, compared with 84 (4.4%) controls. Montelukast usage was significantly associated with reduced odds of exAMD in the multivariable analysis (adjusted odds ratio [OR]: 0.50, 95% confidence interval: 0.31-0.80) and nonsteroidal anti-inflammatory drug usage (adjusted OR: 0.69). Caucasian race, history of smoking, and nonexudative macular degeneration in either eye were also found to have a significant relationship with increased odds of exAMD. In the subanalysis, montelukast usage showed significant association with reduced odds of developing exAMD from nonexudative AMD (adjusted OR: 0.53, 95% confidence interval: 0.29-0.97) and the presence of atopic disease (adjusted OR: 0.60).

Conclusion: The study results suggested that oral montelukast is linked to reduced odds of exAMD development.

PubMed Disclaimer

References

    1. Klein R, Chou CF, Klein BE, et al. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 2011;129:75–80.
    1. Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology 2013;120:844–851.
    1. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292–2299.
    1. Knickelbein JE, Chan CC, Sen HN, et al. Inflammatory mechanisms of age-related macular degeneration. Int Ophthalmol Clin 2015;55:63–78.
    1. Tan W, Zou J, Yoshida S, et al. The role of inflammation in age-related macular degeneration. Int J Biol Sci 2020;16:2989–3001.